# OnCo record five-prime-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/five-prime-therapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "five-prime-therapeutics" ;
  schema:name "Five Prime Therapeutics"@en ;
  schema:alternateName "Five Prime Therapeutics, Inc."@en, "Five Prime"@en, "NASDAQ:FPRX"@en ;
  schema:description "Five Prime Therapeutics developed bemarituzumab, an antibody aimed at a protein called FGFR2b that some stomach cancers carry in large amounts. Amgen bought the company in 2021."@en ;
  schema:url <https://onco.cc/companies/five-prime-therapeutics/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://www.sec.gov/Archives/edgar/data/1175505/000119312521068593/d77427dex991.htm>, <https://www.sec.gov/Archives/edgar/data/1175505/000119312521118566/d153048d8k.htm> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/gastric/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/>, <https://onco.cc/fronts/immunotherapy/> ;
  onco:technologies <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:targets <https://onco.cc/targets/fgfr2/> ;
  onco:drugs <https://onco.cc/drugs/bemarituzumab/> .